What is the Projected CAGR value of the Hemoglobinopathies Market?
Hemoglobinopathies Market is expected to grow at a CAGR of 10.7% during the forecast period 2024-2031.
Who are the Key players contributing to the market's growth?
The Key Players are Gamida Cell, Alnylam Pharmaceuticals, Sanofi, Sangamo Therapeutics Inc., Global Blood Therapeutics, bluebird bio Inc., Emmaus Life Sciences Inc., Prolong Pharmaceuticals, Celgene Corporation, ApoPharma, Bristol-Myers Squibb, Emmaus Medical, Medunik USA and Novartis.